Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 2133.

https://doi.org/10.1182/blood.V128.22.2133.2133

Published: 2016

Journal Articles

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Blood (2016) 128 (22): 2142.

https://doi.org/10.1182/blood.V128.22.2142.2142

Published: 2016

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

Journal Articles

The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma

Shahdabul Faraz, B.S., Roger N Pearse, MD PhD, Sujitha Yadlapati, MBBS, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD MHS, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Joseph Lane, MD

Blood (2015) 126 (23): 5373.

https://doi.org/10.1182/blood.V126.23.5373.5373

Published: 2015

Journal Articles

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Peter Forsberg, MD, Ihsane Ouansafi, MD, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott A Ely, MD MPH

Blood (2014) 124 (21): 2016.

https://doi.org/10.1182/blood.V124.21.2016.2016

Published: 2014

Journal Articles

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Anita D'Souza, MD, Baldeep Wirk, MD, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Cristina J. Gasparetto, MD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 193.

https://doi.org/10.1182/blood.V124.21.193.193

Published: 2014

Journal Articles

A Comparison of Outcomes in the First-Line Treatment of Multiple Myeloma Presenting with Single Versus Multiple Monoclonal Paraproteins

Tomer M Mark, MD MSc, Jason P Meadows, MD, Abbal Koirala, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD

Blood (2014) 124 (21): 2038.

https://doi.org/10.1182/blood.V124.21.2038.2038

Published: 2014

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Abbe Schickner, BA, John N. Allan, MD, Adriana C Rossi, MD, Roger Pearse, MD PhD, Linda Tegnestam, RN, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pognowski, RN, David Jayabalan, BSMS, MSc, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4761.

https://doi.org/10.1182/blood.V124.21.4761.4761

Published: 2014

Journal Articles

Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study

Koen van Besien, MD PhD, Hongtao Liu, MD PhD, Usama Gergis, MD, Melissa M. Cushing, MD, Stephanie Tsai, MD, Sebastian Mayer, MD, Amittha Wickrema, PhD, Wendy Stock, MD, Richard A. Larson, Tsiporah B. Shore, MD, Olatoyosi Odenike, MD, Roger N Pearse, MD PhD, Lucy A Godley, MD PhD, Tomer M Mark, MD MSc, Justin Kline, MD, John M Cunningham, MD, James LaBelle, MD PhD, Michael R Bishop, MD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 1093.

https://doi.org/10.1182/blood.V124.21.1093.1093

Published: 2014

Journal Articles

Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50

Joanna Rhodes, MD, Koen van Besien, MD, Hongtao Liu, MDPhD, Usama Gergis, MD, Stephanie B. Tsai, MD MA, Sebastian Mayer, MD, Wendy Stock, MD, Richard A. Larson, MD, Tsiporah B. Shore, MD, Olatoyosi Odenike, MD, Roger Pearse, MD PhD, Lucy A Godley, MD PhD, Tomer M Mark, MD MSc, Justin Kline, MD, Michael R. Bishop, MD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 1235.

https://doi.org/10.1182/blood.V124.21.1235.1235

Published: 2014

Journal Articles

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Ekta Aneja, MBBS, Adriana C Rossi, MD, Tomer M Mark, MD MSc, David Jayabalan, BSMS, MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Art Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 5778.

https://doi.org/10.1182/blood.V124.21.5778.5778

Published: 2014

Journal Articles

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Luciano J Costa, MD PhD, Geoffrey L. Uy, MD, Parameswaran N. Hari, MD MRCP, MS, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Anita D'Souza, MD

Blood (2014) 124 (21): 2447.

https://doi.org/10.1182/blood.V124.21.2447.2447

Published: 2014

Journal Articles

Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF

John N. Allan, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Adriana C Rossi, MD, Linda Tegnestam, RN, Duane C Hassane, PhD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 2452.

https://doi.org/10.1182/blood.V124.21.2452.2452

Published: 2014

Journal Articles

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Adriana C Rossi, MD, Tomer M Mark, MD, MSc, Kevin Wood, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Stanley Goldsmith, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1878.

https://doi.org/10.1182/blood.V122.21.1878.1878

Published: 2013

Journal Articles

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Angelique Boyer, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1954.

https://doi.org/10.1182/blood.V122.21.1954.1954

Published: 2013

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Dennis Kwon, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1955.

https://doi.org/10.1182/blood.V122.21.1955.1955

Published: 2013

NARROW

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

A Comparison of Outcomes in the First-Line Treatment of Multiple Myeloma Presenting with Single Versus Multiple Monoclonal Paraproteins

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study

Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only